Watch for Bexagliflozin, a New Med for Type 2 Diabetes

September 2023

The new diabetes med, bexagliflozin (Brenzavvy), will pop up on home med lists.

Think of it as similar to other SGLT2 inhibitors for type 2 diabetes...dapagliflozin, empagliflozin, etc.

A big difference is that bexagliflozin will cost about $50/month...versus about $600/month for other SGLT2 inhibitors.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote